Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, sending CRNC shares up nearly 100% on Tuesday. The deal gives Vertex a portfolio of endocrinology assets as the company diversifies beyond its cystic fibrosis franchise.

Crinetics focuses on treatments for rare endocrine diseases and neuroendocrine tumors. The biotech's pipeline includes therapies targeting conditions like acromegaly and Cushing's disease, both marked by hormonal imbalances that affect small patient populations with high unmet medical needs.

The $10 billion price tag represents a significant premium for Crinetics, which nearly doubled in market value on the announcement. For Vertex, the acquisition marks a major expansion into endocrinology after years of dominance in cystic fibrosis treatments. The deal positions Vertex to tap into new revenue streams as it builds out therapeutic areas beyond its core expertise.